{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T08:08:18Z","timestamp":1753862898881,"version":"3.41.2"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Key Clinical Message<\/jats:title><jats:p>This report highlights the risk of latent tuberculosis (TB) reactivation after treatment with Polatuzumab Vedotin (PV), Rituximab, and Bendamustine (PBR protocol) despite appropriate chemoprophylaxis. A 48\u2010year\u2010old male with refractory Burkitt's lymphoma (BKL) was treated with PBR protocol. At baseline, the patient had a negative QuantiFERON test result, which turned out to be positive prior to starting PBR. He received chemoprophylaxis for 9\u2009months and was compliant with treatment. One year later, he was admitted with COVID\u201019 pneumonia and was treated according to the protocol. His symptoms persisted for 1\u2009month. Investigations yielded disseminated TB\u2010infiltrated bone marrow and pleura. Downstream B\u2010cell and T\u2010cell depletion secondary to CD20 and CD79b antagonism may potentially explain the increased risk of TB reactivation associated with the combination of PV and rituximab. Further research is necessary to monitor the risk of TB reactivation among patients receiving a combination of PV and rituximab, especially in endemic areas with high prevalence and incidence of TB.<\/jats:p>","DOI":"10.1002\/ccr3.8838","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T06:29:10Z","timestamp":1715149750000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disseminated tuberculosis after <scp>Polatuzumab\u2010Vedotin<\/scp> based chemoimmunotherapy in a patient with Burkitt's lymphoma"],"prefix":"10.1002","volume":"12","author":[{"given":"Sarah A.","family":"Elkourashy","sequence":"first","affiliation":[{"name":"Hematology Department National Center for Cancer Care and Research, Hamad Medical Corporation  Doha Qatar"},{"name":"Weill Cornell Medical College  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Benkhadra","sequence":"additional","affiliation":[{"name":"Pharmacy Department National Center for Cancer Care and Research, Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"Shafei","sequence":"additional","affiliation":[{"name":"Pharmacy Department National Center for Cancer Care and Research, Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulieman","family":"Abujarir","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, Communicable Disease Center Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1392-8831","authenticated-orcid":false,"given":"Rola","family":"Ghasoub","sequence":"additional","affiliation":[{"name":"Pharmacy Department National Center for Cancer Care and Research, Hamad Medical Corporation  Doha Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2991\/chi.k.210305.001"},{"key":"e_1_2_10_3_1","unstructured":"FDA approval of Polivy (polatuzumab vedotin\u2010piiq) for previously untreated diffuse large B\u2010cell lymphoma not otherwise specified and high\u2010grade B\u2010cell lymphoma2019. Available from:https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010polatuzumab\u2010vedotin\u2010piiq\u2010previously\u2010untreated\u2010diffuse\u2010large\u2010b\u2010cell\u2010lymphoma\u2010no.[Sep 2023]. Food and Drug administration."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01175-0"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30091-9"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14784"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S394193"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmyco.2015.05.015"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.12.344"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149523"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200211002-00002"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103418"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6901a1"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37132004000400015"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken113"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-006585"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153217"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48395-8"},{"issue":"11","key":"e_1_2_10_21_1","article-title":"The prevalence of mycobacterium tuberculosis infection among cancer patients receiving chemotherapy in a tertiary care center","volume":"14","author":"Aldabbagh MA","year":"2022","journal-title":"Cureus"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2008.01282.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.4236\/jtr.2018.61005"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00827"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000000188"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.8838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T05:35:56Z","timestamp":1716960956000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.8838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/ccr3.8838"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.8838","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"type":"print","value":"2050-0904"},{"type":"electronic","value":"2050-0904"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"2023-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e8838"}}